Heart Failure: A Comprehensive Contemporary Review of Definitions, Classification, Pathophysiology, Pharmacologic and Device-Based Management

Heart failure (HF) remains a dominant and escalating cause of cardiovascular morbidity and mortality worldwide, affecting approximately 6.7 million adults in the United States alone, with projections exceeding 8.5 million by 2030. This comprehensive review provides an in-depth, academically rigorous examination of HF, beginning with its fundamental definition as a complex clinical syndrome arising from structural or functional ventricular impairment, rather than a singular disease entity. The article systematically delineates the American College of Cardiology/American Heart Association (ACC/AHA) staging framework—from Stage A (at risk) through Stage D (advanced)—alongside the New York Heart Association (NYHA) functional classification, emphasizing their complementary roles in prognosis and therapeutic decision-making. A detailed exposition of left ventricular ejection fraction (LVEF)-based categorization follows, encompassing heart failure with reduced ejection fraction (HFrEF, LVEF ≤40%), mildly reduced ejection fraction (HFmrEF, LVEF 41–49%), preserved ejection fraction (HFpEF, LVEF ≥50%), and the newly recognized category of heart failure with improved ejection fraction (HFimpEF). The review then addresses the multifactorial etiology of HF across EF strata, including ischemic, nonischemic, genetic, infiltrative, toxic, and metabolic causes, before presenting contemporary epidemiological data highlighting lifetime risks and demographic variations. The pathophysiology section elaborates on maladaptive neurohormonal activation—specifically the renin-angiotensin-aldosterone system and sympathetic nervous system—alongside derangements in calcium handling, energy metabolism, oxidative stress, and inflammatory pathways. Histopathological findings distinctive to various HF etiologies are summarized, including fibrosis, myocyte hypertrophy, disarray, infiltration, and inflammatory patterns. Clinical evaluation, encompassing symptom assessment, physical examination signs (e.g., elevated jugular venous pressure, S3 gallop, pulsus alternans), and diagnostic testing (natriuretic peptides, echocardiography, invasive hemodynamics), is systematically reviewed. The core of the manuscript provides an evidence-based, guideline-directed exposition of pharmacologic therapy, including beta-blockers, angiotensin receptor-neprilysin inhibitors (ARNI), ACE inhibitors, angiotensin receptor blockers, sodium-glucose cotransporter-2 inhibitors (SGLT2i), mineralocorticoid receptor antagonists, hydralazine/nitrates, ivabradine, vericiguat, digoxin, diuretics, and intravenous iron, with explicit recommendations stratified by LVEF and supporting trial data. Non-pharmacologic and device-based interventions—implantable cardioverter-defibrillators (ICD), cardiac resynchronization therapy (CRT), coronary revascularization, transcatheter edge-to-edge mitral valve repair (TEER), pulmonary artery pressure monitoring (CardioMEMS), catheter ablation, ventricular assist devices (VAD), and heart transplantation—are discussed with attention to indications and outcomes. The management of acute decompensated heart failure (ADHF) and cardiogenic shock, including the SCAI staging system and Forrester classification, is detailed. Finally, the review addresses differential diagnosis, treatment planning, adverse effect management, prognosis, complications, patient education, and the critical importance of an interprofessional, team-based approach to improving outcomes in this high-burden cardiovascular condition.